Agilent traded at $128.18 this Wednesday February 11th, decreasing $0.82 or 0.64 percent since the previous trading session. Looking back, over the last four weeks, Agilent lost 13.39 percent. Over the last 12 months, its price fell by 7.17 percent. Looking ahead, we forecast Agilent to be priced at 125.60 by the end of this quarter and at 114.39 in one year, according to Trading Economics global macro models projections and analysts expectations.
Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. The Company’s business segments include life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. The life sciences and applied markets business segment provides application-focused solutions that include instruments and software. The Company's diagnostics and genomics business segment includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses. The Company's Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.